Table 1 Clinical parameters of COPD patients participating in the study.

From: NT-proCNP as a new biomarker of pulmonary hypertension in patients with COPD

Variable

All COPD patients

(n = 94)

COPD patients without PH

(n = 42)

COPD patients with PH

(n = 52)

P value*

Age, years

63.5 ± 7.5

63.4 ± 8.2

63.5 ± 6.9

0.89

Sex, male/female

84/10

36/6

48/4

0.16

BMI, kg/m2

23.7 ± 3.6

23.97 ± 4.3

23.2 ± 2.1

0.87

COPD duration, years

13.2 ± 6.1

14.98 ± 8.7

11.8 ± 5.4

0.09

Frequency of exacerbations, n/year

1,99 ± 0,77

1.8 ± 0.8

2.2 ± 0.7

0.08

Smoking history, pack-years

25.2 ± 6.9

23.6 ± 6.8

27.4 ± 6.9

0.07

FEV1, % predicted

33.7 ± 10.2

38.9 ± 9.4

29.6 ± 8.9

0.001

FVC, % predicted

62.1 ± 16.7

64.9 ± 16.9

60.7 ± 16.1

0.17

FEV1/FVC, %

44.7 ± 10.2

46.3 ± 10.4

43.9 ± 9.7

0.19

mMRC, points

3.2 ± 0.5

3.2 ± 0.3

3.3 ± 0.5

0.002

CAT, points

28.0 ± 6.2

23.4 ± 4.2

31.7 ± 4.9

< 0.001

SpO2, %

91.2 ± 5.95

93.1 ± 2.9

90.2 ± 6.4

< 0.001

Distance in 6MWT, m

232.1 ± 46.3

242.9 ± 25.9

221.5 ± 56.1

0.005

SPAP, mmHg

42.4 ± 13.9

29.4 ± 4.7

52.9 ± 8.9

< 0.001

MPAP, mmHg

27.3 ± 9.7

17.6 ± 1.4

34.9 ± 5.9

< 0.001

CRP, mg/L

2.4 ± 0.8

1.5 ± 0.8

2.8 ± 0.5

< 0.001

Fibrinogen, mg/L

4.7 ± 2.1

2.8 ± 0.8

6.3 ± 1.4

< 0.001

  1. * difference between patients with and without PH.
  2. BMI, body mass index; FVC, forced vital capacity; FEV1, forced expiratory volume at 1 s; CAT, COPD assessment test; SpO2, oxygen saturation; 6MWT, 6-minute walk test; SPAP, pulmonary artery systolic pressure, MPAP, mean pulmonary artery pressure, CRP, C-reactive protein.
Back to article page